{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Rochester&page=81&state=Minnesota",
    "query": {
      "state": "Minnesota",
      "city": "Rochester",
      "page": 81
    },
    "page_size": 10
  },
  "pagination": {
    "page": 81,
    "page_size": 10,
    "total_count": 9159,
    "total_pages": 916,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Rochester&page=82&state=Minnesota&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Rochester&page=80&state=Minnesota&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T06:17:55.682Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02178241",
      "title": "Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Ureter Carcinoma",
        "Metastatic Urethral Carcinoma",
        "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage III Ureter Cancer AJCC v7",
        "Stage III Urethral Cancer AJCC v7",
        "Stage IV Bladder Urothelial Carcinoma AJCC v7",
        "Stage IV Ureter Cancer AJCC v7",
        "Stage IV Urethral Cancer AJCC v7",
        "Ureter Urothelial Carcinoma",
        "Urethral Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Eribulin Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2014-12-11",
      "completion_date": "2019-07-11",
      "has_results": true,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-11-19T06:17:55.682Z",
      "location_count": 17,
      "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178241"
    },
    {
      "nct_id": "NCT05662345",
      "title": "ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "CellSearch Circulating Tumor Cells",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Menarini Silicon Biosystems, INC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2022-12-12",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-11-19T06:17:55.682Z",
      "location_count": 4,
      "location_summary": "Albert Lea, Minnesota • Mankato, Minnesota • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Albert Lea",
          "state": "Minnesota"
        },
        {
          "city": "Mankato",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Eau Claire",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05662345"
    },
    {
      "nct_id": "NCT00948675",
      "title": "Study of Participants With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 361,
      "start_date": "2009-09-01",
      "completion_date": "2020-11-06",
      "has_results": true,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-11-19T06:17:55.682Z",
      "location_count": 45,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Mission Hills, California + 42 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00948675"
    },
    {
      "nct_id": "NCT02660112",
      "title": "(+) Epicatechin to Treat Friedreich's Ataxia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Friedreich's Ataxia"
      ],
      "interventions": [
        {
          "name": "(+)-Epicatechin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ralitza Gavrilova",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "10 Years to 50 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-09",
      "completion_date": "2018-12-30",
      "has_results": true,
      "last_update_posted_date": "2019-12-05",
      "last_synced_at": "2026-11-19T06:17:55.682Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02660112"
    },
    {
      "nct_id": "NCT00110019",
      "title": "Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mucosal Melanoma",
        "Recurrent Melanoma",
        "Stage IIIA Skin Melanoma",
        "Stage IIIB Skin Melanoma",
        "Stage IIIC Skin Melanoma",
        "Stage IV Skin Melanoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 823,
      "start_date": "2005-06",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2015-10-19",
      "last_synced_at": "2026-11-19T06:17:55.682Z",
      "location_count": 218,
      "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 175 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110019"
    },
    {
      "nct_id": "NCT05081128",
      "title": "Efficacy in iNPH Shunting (PENS) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Idiopathic Normal Pressure Hydrocephalus (INPH)"
      ],
      "interventions": [
        {
          "name": "programmable CSF shunt valve",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2022-05-18",
      "completion_date": "2026-02-24",
      "has_results": true,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-11-19T06:17:55.682Z",
      "location_count": 14,
      "location_summary": "Davis, California • Los Angeles, California • Santa Monica, California + 10 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05081128"
    },
    {
      "nct_id": "NCT00550862",
      "title": "Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cirrhosis, Biliary"
      ],
      "interventions": [
        {
          "name": "INT-747",
          "type": "DRUG"
        },
        {
          "name": "Ursodeoxycholic Acid (URSO)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 165,
      "start_date": "2007-10",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2024-02-06",
      "last_synced_at": "2026-11-19T06:17:55.682Z",
      "location_count": 13,
      "location_summary": "Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Novi",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00550862"
    },
    {
      "nct_id": "NCT01403194",
      "title": "Continuous Positive Airway Pressure and Cardiometabolic Risk",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sleep Disordered Breathing"
      ],
      "interventions": [
        {
          "name": "CPAP/BiPAP",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "8 Years to 18 Years"
      },
      "enrollment_count": 11,
      "start_date": "2011-03",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-05-13",
      "last_synced_at": "2026-11-19T06:17:55.682Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01403194"
    },
    {
      "nct_id": "NCT05751629",
      "title": "Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Neoplasm"
      ],
      "interventions": [
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 41,
      "start_date": "2018-11-15",
      "completion_date": "2022-04-01",
      "has_results": true,
      "last_update_posted_date": "2023-04-21",
      "last_synced_at": "2026-11-19T06:17:55.682Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05751629"
    },
    {
      "nct_id": "NCT01658995",
      "title": "Management of Etonogestrel Subdermal Implant-related Bleeding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ESI-related Bleeding"
      ],
      "interventions": [
        {
          "name": "Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Petra M. Casey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 51 Years · Female only"
      },
      "enrollment_count": 82,
      "start_date": "2012-09-13",
      "completion_date": "2019-12-30",
      "has_results": true,
      "last_update_posted_date": "2021-01-26",
      "last_synced_at": "2026-11-19T06:17:55.682Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658995"
    }
  ]
}